SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc., (Nasdaq:AFFX) announced today that scientists at Cancer Research UK have used Affymetrix technology to discover the molecular basis for tamoxifen response in breast cancer cells - and the reason why some women can develop resistance to the treatment. Their findings are published in Nature.
